SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request Mar 2, 2017
SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors Jan 26, 2017
SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections Dec 13, 2016
SCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference Dec 12, 2016
SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078 Oct 25, 2016
SCYNEXIS Announces Complete Results from Two Phase 2 Studies of Oral SCY-078 in Patients with Candida spp. Infections and Closing of a $15 Million Term Loan Oct 5, 2016
